Time to take profits in Eagle Pharmaceuticals
I am sending out this update to the Small Cap Gems community as I wanted to make an announcement that Eagle Pharmaceuticals (NASDAQ: EGRX) is being removed from our top 20 list now that the shares have surpassed $80 a share. It has been a fantastic run riding this rocket. However after a better than 460% return in approximately six months, it is time to put Eagle in our all-time champions list and look for hopefully similar opportunities.
This does not mean I have changed my tune on the company’s long term prospects and I plan to hold my remaining 50% stake in the company over the long term. I just think the stock has had a remarkable rally and it could be vulnerable should sentiment shift on the small biotech space which looks like it is has gotten frothy in recent months.
This seems an appropriate time to re-emphasize a couple of core philosophies I try to consistently articulate to subscribers in high beta sectors especially biotech. The first is that this is an extremely complicated sector of the market prone to bouts of exuberance usually followed by fear induced pull backs like that of March 2014. The fact is most new drugs never make it out of the approval process, leading to high rates of failure. Hundreds of companies are spending tens of billions of dollars a year to develop new compounds. In 2014, the FDA only approved 41 new drugs.
This is why I believe one must practice what I have dubbed “shotgun investing” in this volatile area in the market. This consists of taking myriad small positions in a variety of promising but speculative companies in the space. One must go into this exercise knowing that there will be quite a few flameouts along the way. However, the occasional grand slam like Eagle will lead to a solid return over time.
Second, one must know when to take some profits on winners. There are three mistakes that can crater an investor’s overall returns over time in the small cap biotech arena. The first is when a stock implodes because a company’s compound fails in trials. Unfortunately, there is not much you can do about that outside of initial research and maintaining a well-diversified portfolio.
The second mistake is when a stock like Eagle soars and you take no profits along the way. Many times, these rockets come back to Earth and you feel like a darn fool for not taking some gains. However, the biggest mistake is cashing out entirely. Having an equity with a $250 million market capitalization grow to being worth $1 billion in short order is a great feeling. Cashing out completely and watching the same company grow to a $10 billion or bigger behemoth is a sickening one.
This is why I have developed the “Jensen Rules” to force myself to employ a prudent investing strategy in this volatile area of the market. After a 50% return, I cash out 10% of my original share position. If the stock doubles, I take 20% more of the original stake off the table. If I am lucky enough to get a triple, I sell the last 20% of the original position. This leaves me with half of my original position riding on the “house’s money” after booking a guaranteed gain on the position even if the stock goes to zero. As importantly, it keeps me from throwing away the next Gilead Sciences (NASDAQ: GILD). I highly urge subscribers to do the same.
Eagle has been a huge winner for Small Cap Gems and hopefully the remaining 50% of your stake continues to grow over time. We raise our glass to its performance and now will focus on finding a new selection that offers the possibility of similar returns.
We’ve had a number of winners in this space since launching Small Cap Gems, including Avanir closing with a 215% gain, Agenus up 227%, Progenics up 38%, OncoGenex up 20%. We’ve also had a couple of laggards, notably Endocyte and Conatus, though the latter is starting to move in the right direction again. I have faith those two will reward us over time as part of our overall strategy, but that’s also why as I mentioned in the beginning of this update that we hold multiple positions in this sector: one Eagle at 464% more than makes up for both Endocyte and Conatus.
For those who are new to Small Cap Gems or have missed the announcements, last month I beta launched a new service dedicated solely to the biotech sector, aptly named Biotech Gems. This exciting newsletter is focused exclusively on the high flying biotech sector and contains stocks that could be the next Eagle, Agenus, and so on. If you’re interested in being a beta tester and early subscriber just click here for a short description of the service and a link to sign up.